Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICUSource: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003
Association of acinetobacter baumannii respiratory isolates with hospital outcomes in ventilated patients Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Acinetobacter baumannii infection and colonization among pediatric patients in pediatric ICU and other ICUs Source: International Congress 2018 – Neonatology and paediatric intensive care Year: 2018
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Direct LAMP assay from clinical sample for carbapenem resistant A. baumannii Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007
Clinical outcomes of the patients with multidrug-resistant Acinetobacter baumannii pneumonia in critical care setting: A retrospective cohort study in Taiwan Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
Inhaled colistin on Acinetobacter baumannii treatment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Activity of N-acetylcysteine in combination with colistin against a collection of colistin resistant Acinetobacter baumannii clinical isolates Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017
Previous antibacterial therapy and drug-resistance among pathogens in ICU patients with nosocomial pneumonia Source: Eur Respir J 2001; 18: Suppl. 33, 405s Year: 2001
Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults. Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017
Study on the molecular epidemiology of stenotrophomonas maltophilia infection in patients on mechanical ventilation Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006
Acinetobacter baumanii as a severity marker in a respiratory ICUSource: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006
Prognosis of Acinetobacter baumannii bacteraemia in a respiratory ICU: 10 years‘ experience Source: Eur Respir J 2005; 26: Suppl. 49, 222s Year: 2005
Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006
Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 58s Year: 2005
The resistance rates of Acinetobacter baumannii at endotracheal aspirate cultures Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012